Cargando…
Timing of Antiviral Treatment Initiation is Critical to Reduce SARS‐CoV‐2 Viral Load
We modeled the viral dynamics of 13 untreated patients infected with severe acute respiratory syndrome‐coronavirus 2 to infer viral growth parameters and predict the effects of antiviral treatments. In order to reduce peak viral load by more than two logs, drug efficacy needs to be > 90% if treat...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323384/ https://www.ncbi.nlm.nih.gov/pubmed/32558354 http://dx.doi.org/10.1002/psp4.12543 |
_version_ | 1783551771852931072 |
---|---|
author | Gonçalves, Antonio Bertrand, Julie Ke, Ruian Comets, Emmanuelle de Lamballerie, Xavier Malvy, Denis Pizzorno, Andrés Terrier, Olivier Rosa Calatrava, Manuel Mentré, France Smith, Patrick Perelson, Alan S. Guedj, Jérémie |
author_facet | Gonçalves, Antonio Bertrand, Julie Ke, Ruian Comets, Emmanuelle de Lamballerie, Xavier Malvy, Denis Pizzorno, Andrés Terrier, Olivier Rosa Calatrava, Manuel Mentré, France Smith, Patrick Perelson, Alan S. Guedj, Jérémie |
author_sort | Gonçalves, Antonio |
collection | PubMed |
description | We modeled the viral dynamics of 13 untreated patients infected with severe acute respiratory syndrome‐coronavirus 2 to infer viral growth parameters and predict the effects of antiviral treatments. In order to reduce peak viral load by more than two logs, drug efficacy needs to be > 90% if treatment is administered after symptom onset; an efficacy of 60% could be sufficient if treatment is initiated before symptom onset. Given their pharmacokinetic/pharmacodynamic properties, current investigated drugs may be in a range of 6–87% efficacy. They may help control virus if administered very early, but may not have a major effect in severely ill patients. |
format | Online Article Text |
id | pubmed-7323384 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73233842020-06-29 Timing of Antiviral Treatment Initiation is Critical to Reduce SARS‐CoV‐2 Viral Load Gonçalves, Antonio Bertrand, Julie Ke, Ruian Comets, Emmanuelle de Lamballerie, Xavier Malvy, Denis Pizzorno, Andrés Terrier, Olivier Rosa Calatrava, Manuel Mentré, France Smith, Patrick Perelson, Alan S. Guedj, Jérémie CPT Pharmacometrics Syst Pharmacol Research We modeled the viral dynamics of 13 untreated patients infected with severe acute respiratory syndrome‐coronavirus 2 to infer viral growth parameters and predict the effects of antiviral treatments. In order to reduce peak viral load by more than two logs, drug efficacy needs to be > 90% if treatment is administered after symptom onset; an efficacy of 60% could be sufficient if treatment is initiated before symptom onset. Given their pharmacokinetic/pharmacodynamic properties, current investigated drugs may be in a range of 6–87% efficacy. They may help control virus if administered very early, but may not have a major effect in severely ill patients. John Wiley and Sons Inc. 2020-08-07 2020-09 /pmc/articles/PMC7323384/ /pubmed/32558354 http://dx.doi.org/10.1002/psp4.12543 Text en © 2020 The Authors. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Research Gonçalves, Antonio Bertrand, Julie Ke, Ruian Comets, Emmanuelle de Lamballerie, Xavier Malvy, Denis Pizzorno, Andrés Terrier, Olivier Rosa Calatrava, Manuel Mentré, France Smith, Patrick Perelson, Alan S. Guedj, Jérémie Timing of Antiviral Treatment Initiation is Critical to Reduce SARS‐CoV‐2 Viral Load |
title | Timing of Antiviral Treatment Initiation is Critical to Reduce SARS‐CoV‐2 Viral Load |
title_full | Timing of Antiviral Treatment Initiation is Critical to Reduce SARS‐CoV‐2 Viral Load |
title_fullStr | Timing of Antiviral Treatment Initiation is Critical to Reduce SARS‐CoV‐2 Viral Load |
title_full_unstemmed | Timing of Antiviral Treatment Initiation is Critical to Reduce SARS‐CoV‐2 Viral Load |
title_short | Timing of Antiviral Treatment Initiation is Critical to Reduce SARS‐CoV‐2 Viral Load |
title_sort | timing of antiviral treatment initiation is critical to reduce sars‐cov‐2 viral load |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323384/ https://www.ncbi.nlm.nih.gov/pubmed/32558354 http://dx.doi.org/10.1002/psp4.12543 |
work_keys_str_mv | AT goncalvesantonio timingofantiviraltreatmentinitiationiscriticaltoreducesarscov2viralload AT bertrandjulie timingofantiviraltreatmentinitiationiscriticaltoreducesarscov2viralload AT keruian timingofantiviraltreatmentinitiationiscriticaltoreducesarscov2viralload AT cometsemmanuelle timingofantiviraltreatmentinitiationiscriticaltoreducesarscov2viralload AT delamballeriexavier timingofantiviraltreatmentinitiationiscriticaltoreducesarscov2viralload AT malvydenis timingofantiviraltreatmentinitiationiscriticaltoreducesarscov2viralload AT pizzornoandres timingofantiviraltreatmentinitiationiscriticaltoreducesarscov2viralload AT terrierolivier timingofantiviraltreatmentinitiationiscriticaltoreducesarscov2viralload AT rosacalatravamanuel timingofantiviraltreatmentinitiationiscriticaltoreducesarscov2viralload AT mentrefrance timingofantiviraltreatmentinitiationiscriticaltoreducesarscov2viralload AT smithpatrick timingofantiviraltreatmentinitiationiscriticaltoreducesarscov2viralload AT perelsonalans timingofantiviraltreatmentinitiationiscriticaltoreducesarscov2viralload AT guedjjeremie timingofantiviraltreatmentinitiationiscriticaltoreducesarscov2viralload |